Last reviewed · How we verify

Lorviqua — Competitive Intelligence Brief

Lorviqua (lorviqua) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: As provided in real world practice. Area: Oncology.

preclinical As provided in real world practice Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1 Oncology Live · refreshed every 30 min

Target snapshot

Lorviqua (lorviqua) — Pfizer Inc.. As provided in real world practice

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lorviqua TARGET lorviqua Pfizer Inc. preclinical As provided in real world practice Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (As provided in real world practice class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lorviqua — Competitive Intelligence Brief. https://druglandscape.com/ci/lorviqua. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing